MORGAN STANLEY PLC/CALL/ASTRAZENECA ADR/95/0.1/21.03.25 | Real-time Bid/Ask 03:16:15 2024-06-11 EDT | ||
| 0.208 EUR / 0.228 EUR | +2.83% |
|
| Current month | +32.50% | ||
| 1 month | +40.40% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
ASTRAZENECA PLC
Latest news about ASTRAZENECA PLC
More news
| Date | Price | Change |
|---|---|---|
| 24-06-11 | 0.208 | -1.89% |
| 24-06-10 | 0.212 | +3.92% |
| 24-06-07 | 0.204 | -4.67% |
| 24-06-06 | 0.214 | -1.38% |
| 24-06-05 | 0.217 | +9.05% |
Delayed Quote Börse Stuttgart
Last update June 11, 2024 at 02:44 am
More quotesStatic data
| Product type | Plain-Vanilla-Warrants |
|---|---|
| Buy / Sell | CALL |
| Underlying | ASTRAZENECA PLC |
| Issuer | Morgan Stanley |
| WKN | MG39KJ |
| ISIN | DE000MG39KJ5 |
| Date issued | 2024-04-30 |
| Strike | 95 $ |
| Maturity | 2025-03-21 (284 Days) |
| Parity | 10 : 1 |
| Emission price | 0.17 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 0.219 € |
|---|---|
| Lowest since issue | 0.116 € |
| Spread | 0.02 € |
| Spread % | 8.70% |
Company Profile
AstraZeneca PLC is one of the world's leading pharmaceutical groups. Net sales break down by source of income as follows:
- product sales (95.6%). Net sales break down by treatment area between oncology (39.2%), cardiovascular, renal and metabolic diseases (24.2%), respiratory and autoimmune diseases (13.9%), and other (22.7%; inflammatory diseases, neurological diseases, gastrointestinal and infectious diseases);
- collaboration revenue (4.4%).
Net sales are distributed geographically as follows: the United Kingdom (7.4%), Europe (21.2%), America (45.3%) and Africa-Asia-Australia (26.1%).
Sector
-
Consensus: AstraZeneca PLC
Sell
Buy
Mean consensus
BUY
Number of Analysts
23
Last Close Price
160.3
USD
Average target price
174.4
USD
Spread / Average Target
+8.77%
- Stock Market
- Warrants
- Warrant
